Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 20, 2022

SELL
$69.73 - $142.9 $117,495 - $240,786
-1,685 Closed
0 $0
Q4 2021

Feb 02, 2022

BUY
$134.56 - $217.97 $47,768 - $77,379
355 Added 26.69%
1,685 $241,000
Q3 2021

Oct 28, 2021

BUY
$177.8 - $270.58 $19,558 - $29,763
110 Added 9.02%
1,330 $276,000
Q2 2021

Aug 13, 2021

BUY
$121.0 - $257.67 $147,620 - $314,357
1,220 New
1,220 $259,000
Q1 2021

May 06, 2021

SELL
$112.98 - $319.93 $289,115 - $818,700
-2,559 Closed
0 $0
Q4 2020

Feb 09, 2021

BUY
$78.74 - $139.5 $48,818 - $86,490
620 Added 31.98%
2,559 $285,000
Q3 2020

Nov 03, 2020

SELL
$79.44 - $178.51 $62,042 - $139,416
-781 Reduced 28.71%
1,939 $210,000
Q2 2020

Jul 31, 2020

BUY
$13.86 - $83.61 $37,699 - $227,419
2,720 New
2,720 $227,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $704M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Sigma Planning Corp Portfolio

Follow Sigma Planning Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.